ASX:ZNO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Zoono Group Limited, together with its subsidiaries, engages in the research, development, and sale of a range of antimicrobial products worldwide. More Details


Snowflake Analysis

Flawless balance sheet and undervalued.

Share Price & News

How has Zoono Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ZNO is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ZNO's weekly volatility has decreased from 20% to 10% over the past year.


Market Performance


7 Day Return

-3.2%

ZNO

-2.0%

AU Chemicals

0.5%

AU Market


1 Year Return

458.3%

ZNO

-24.3%

AU Chemicals

0.9%

AU Market

Return vs Industry: ZNO exceeded the Australian Chemicals industry which returned -24.3% over the past year.

Return vs Market: ZNO exceeded the Australian Market which returned 0.9% over the past year.


Shareholder returns

ZNOIndustryMarket
7 Day-3.2%-2.0%0.5%
30 Day-9.2%9.9%9.3%
90 Day-30.0%3.1%12.3%
1 Year466.9%458.3%-23.6%-24.3%4.3%0.9%
3 Year318.6%312.3%-22.4%-26.0%23.0%7.9%
5 Yearn/a-11.3%-19.6%59.8%27.5%

Long-Term Price Volatility Vs. Market

How volatile is Zoono Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zoono Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ZNO (A$1.34) is trading below our estimate of fair value (A$2.96)

Significantly Below Fair Value: ZNO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ZNO is good value based on its PE Ratio (13.9x) compared to the AU Chemicals industry average (33.2x).

PE vs Market: ZNO is good value based on its PE Ratio (13.9x) compared to the Australian market (22.7x).


Price to Earnings Growth Ratio

PEG Ratio: ZNO is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: ZNO is overvalued based on its PB Ratio (11x) compared to the AU Chemicals industry average (3.3x).


Next Steps

Future Growth

How is Zoono Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

17.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZNO's forecast earnings growth (17.3% per year) is above the savings rate (2.3%).

Earnings vs Market: ZNO's earnings (17.3% per year) are forecast to grow slower than the Australian market (18.5% per year).

High Growth Earnings: ZNO's earnings are forecast to grow, but not significantly.

Revenue vs Market: ZNO's revenue (17.5% per year) is forecast to grow faster than the Australian market (5.2% per year).

High Growth Revenue: ZNO's revenue (17.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ZNO's Return on Equity is forecast to be very high in 3 years time (46.3%).


Next Steps

Past Performance

How has Zoono Group performed over the past 5 years?

77.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ZNO has a high level of non-cash earnings.

Growing Profit Margin: ZNO became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ZNO's earnings have grown significantly by 77% per year over the past 5 years.

Accelerating Growth: ZNO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ZNO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (-4.2%).


Return on Equity

High ROE: ZNO's Return on Equity (79.5%) is considered outstanding.


Next Steps

Financial Health

How is Zoono Group's financial position?


Financial Position Analysis

Short Term Liabilities: ZNO's short term assets (NZ$32.9M) exceed its short term liabilities (NZ$12.4M).

Long Term Liabilities: ZNO's short term assets (NZ$32.9M) exceed its long term liabilities (NZ$1.4M).


Debt to Equity History and Analysis

Debt Level: ZNO is debt free.

Reducing Debt: ZNO had no debt 5 years ago.

Debt Coverage: ZNO has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ZNO has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Zoono Group current dividend yield, its reliability and sustainability?

2.27%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: ZNO's dividend (2.27%) is higher than the bottom 25% of dividend payers in the Australian market (2.07%).

High Dividend: ZNO's dividend (2.27%) is low compared to the top 25% of dividend payers in the Australian market (5%).


Stability and Growth of Payments

Stable Dividend: Too early to tell whether ZNO's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if ZNO's dividend payments are increasing as they only just started paying a dividend.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (31.5%), ZNO's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: ZNO's dividends in 3 years are forecast to be well covered by earnings (46.9% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average board tenure


CEO

Paul Hyslop

no data

Tenure

NZ$427,938

Compensation

Mr. Paul Hyslop has been the Managing Director and Director of Zoono Group Limited since April 26, 2017 and serves as its Chief Executive Officer. Mr. Hyslop's primary responsibility is to determine the st...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD301.49K) is below average for companies of similar size in the Australian market ($USD525.48K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Paul Hyslop
CEO, MD & Directorno dataNZ$427.94k40.68%
NZ$ 89.2m
Elissa Hansen
Company Secretary & Independent Non-Executive Director5.17yrsNZ$65.23k0.17%
NZ$ 369.8k
Donald Clarke
Non-Executive Independent Director3.67yrsNZ$65.23k0.17%
NZ$ 361.8k

3.7yrs

Average Tenure

Experienced Board: ZNO's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Zoono Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zoono Group Limited
  • Ticker: ZNO
  • Exchange: ASX
  • Founded: 1986
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: AU$219.241m
  • Shares outstanding: 163.61m
  • Website: https://zoono.com

Location

  • Zoono Group Limited
  • 24 Bishop Dunn Place
  • Botany South
  • Auckland
  • 2013
  • New Zealand

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZNOASX (Australian Securities Exchange)YesOrdinary SharesAUAUDMay 2017
ZNOCHIA (Chi-X Australia)YesOrdinary SharesAUAUDMay 2017
ZNOG.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 2017

Biography

Zoono Group Limited, together with its subsidiaries, engages in the research, development, and sale of a range of antimicrobial products worldwide. The company’s products include hand sanitizers, textile a...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/05 07:07
End of Day Share Price2020/12/04 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.